"Phenylthiohydantoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Thiohydantoin benzene derivative.
| Descriptor ID |
D010669
|
| MeSH Number(s) |
D03.383.129.308.432.555.868.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Phenylthiohydantoin".
Below are MeSH descriptors whose meaning is more specific than "Phenylthiohydantoin".
This graph shows the total number of publications written about "Phenylthiohydantoin" by people in this website by year, and whether "Phenylthiohydantoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 3 | 1 | 4 |
| 2018 | 3 | 1 | 4 |
| 2019 | 2 | 2 | 4 |
| 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Phenylthiohydantoin" by people in Profiles.
-
The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat Commun. 2021 07 01; 12(1):4068.
-
Androgen regulation of pulmonary AR, TMPRSS2 and ACE2 with implications for sex-discordant COVID-19 outcomes. Sci Rep. 2021 05 27; 11(1):11130.
-
COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Mar 16; 22(1):209.
-
Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021 02 08; 12(1):866.
-
Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer. Eur Urol. 2020 01; 77(1):132-133.
-
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Res. 2019 May; 39(5):2467-2473.
-
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs. 2019 Mar; 79(4):381-400.
-
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. Cancer Treat Rev. 2019 Mar; 74:35-42.
-
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. Eur Urol. 2018 11; 74(5):562-572.
-
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target. J Oral Pathol Med. 2018 Aug; 47(7):691-695.